RLMD: Relmada Therapeutics, Inc. Stock

by  •  • Comments Off on RLMD: Relmada Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 12.07
Enterprise Value ($M) 10.59
Book Value ($M) 47.63
Book Value / Share 1.58
Price / Book 0.25
NCAV ($M) 47.60
NCAV / Share 1.58
Price / NCAV 0.25

Profitability (mra)
Return on Invested Capital (ROIC) -1.82
Return on Assets (ROA) -0.89
Return on Equity (ROE) -1.01

Liquidity (mrq)
Quick Ratio 6.89
Current Ratio 6.89

Balance Sheet (mrq) ($M)
Current Assets 55.70
Assets 55.72
Liabilities 8.10
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Deep Track Capital, LP 2.24 -66.99
03-06 13G/A Perceptive Advisors Llc 0.00 -100.00
02-14 13G/A Rtw Investments, Lp 0.00 -100.00
02-13 13G/A Vanguard Group Inc 4.35 -13.59

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-19 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Fo

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-15 70,873 228,926 30.96
2025-01-14 186,165 401,363 46.38
2025-01-13 151,090 512,150 29.50
2025-01-10 71,762 516,899 13.88

(click for more detail)

Similar Companies
RGEN – Repligen Corporation RGNX – REGENXBIO Inc.
RIGL – Rigel Pharmaceuticals, Inc. RLYB – Rallybio Corporation
ROIV – Roivant Sciences Ltd.


Financial data and stock pages provided by
Fintel.io